✦ LIBER ✦

Targeted therapy and pharmacogenomic programs

✍ Scribed by Syma Iqbal; Heinz Josef Lenz

Publisher: John Wiley and Sons
Year: 2003
Tongue: English
Weight: 94 KB
Volume: 97
Category: Article
ISSN: 0008-543X
DOI: 10.1002/cncr.11287

No coin nor oath required. For personal study only.

✦ Synopsis

The goal in administering chemotherapeutics is to develop the ability to predict the outcome of therapy in terms of response and toxicity. Technology has been developed to allow tumor profiling with measurement of protein expression, gene expression levels of markers, and even genetic polymorphisms, which may predict response to particular chemotherapeutics. The chemotherapeutics for which particular markers have been shown to predict outcome include the fluoropyrimidines and platinums. The next step is to develop clinical trials that will assess prospectively the benefits of profiling a patient's particular tumor, which should translate into an improvement in response and toxicity.

📜 SIMILAR VOLUMES

Targeted photodynamic therapy

✍ Nicolas Solban; Imran Rizvi; Tayyaba Hasan 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 195 KB

## Abstract ## Background and Objectives Photodynamic therapy (PDT) is an emerging modality for the treatment of various neoplastic and non‐neoplastic pathologies. ## Study Design/Materials and Methods PDT usually occurs when reactive oxygen species (ROS) generated from light‐activated chemicals

Session 3: Targeted therapy

📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 French ⚖ 102 KB

## Introduction: The Glucagon-like-Peptide-1 (GLP-1) receptor is an interesting target in tumor diagnosis and therapy with Exendin-based radiopeptides as it is overexpressed on human insulinomas and gastrinomas. We have recently shown high therapeutic efficacy using a radiopeptide labeled with the

Molecularly targeted therapy and cancer

Molecularly targeted therapy and cancer surgery

✍ I. Judson; J. Barriuso 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 48 KB 👁 2 views

Molecular targeting and pharmacogenomics

Molecular targeting and pharmacogenomics in the management of advanced bladder cancer

✍ Derek Raghavan 📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 English ⚖ 88 KB 👁 1 views

Bladder cancer is one of the malignancies for which considerable information is available regarding molecular pathogenesis and genetic predictors of natural history, as well as response to treatment. Loss of heterozygosity of chromosome 9 appears to be essential to the genesis of superficial bladder

Chromophore-assisted laser inactivation

Chromophore-assisted laser inactivation (CALI) to validate drug targets and pharmacogenomic markers

✍ Leodevico L. Ilag; Jocelyn H. Ng; Daniel G. Jay 📂 Article 📅 2000 🏛 John Wiley and Sons 🌐 English ⚖ 141 KB

Functional proteomics directly addresses the role of proteins in cellular processes and thereby provides a basis for target validation for the development of therapeutics against particular diseases. Validated protein targets may serve as ideal pharmacogenomics markers. Chromophore-assisted laser in

Targeted therapy in pediatric and adoles

Targeted therapy in pediatric and adolescent oncology

✍ Mark L. Bernstein 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 946 KB

## Abstract Cancers in children and adolescents are fortunately infrequent. Overall, cure rates are good, approximately 80%, although this varies by histology and stage. Targeted therapies aim to improve efficacy and decrease toxicity by more specifically affecting malignant cells or their supporti